Clinicians Prioritize Established Disease Risk Assessments Over Biological Age Estimates

On October 18, 2026, Emirates 24|7 published a report on clinicians’ concerns about diagnosing premature aging in healthy people through biological-age testing and the value of established disease-risk assessment.

Why disease risk and an age score answer different questions

Dr Iman Abi Al-Surur told Emirates 24|7 that no single approved test accurately determines biological age or diagnoses premature aging in a healthy person. She instead highlighted established indicators that help assess disease risk. Separately, Stanford Medicine says direct-to-consumer biological-age clocks are not FDA-approved medical diagnostic tools and are sold as wellness or informational products. The report’s relevance to healthspan is therefore a distinction between assessing recognizable health risks and assigning an age estimate, rather than a finding that a test or intervention helps people remain healthy longer.

How to identify the evidence behind the headline

Evidence setting: Human clinical observations and expert commentary, not a study conducted in vitro, in animal models or in a human clinical trial.

Emirates 24|7 reported that clinicians were seeing diabetes and high blood pressure in people under 30. It also described their observations of diseases previously more common after 50 appearing in patients in their 30s or younger. Those comments formed the clinical background to the discussion about premature aging.

Stanford Medicine’s separate account addresses the scientific and consumer-testing context. It describes biological-age clocks as research tools whose interpretation and possible use in evaluating interventions remain under investigation. Reading the two accounts together brings a clinical question about disease risk alongside a research question about measuring aging, without making them the same question.

Why the evidence needs a narrower reading

The useful interpretation starts with the boundaries of each source. The following limitations concern different parts of the story, from the reported patient observations to the meaning of a consumer test result.

• Clinical observations do not establish a population-wide trend. The Emirates 24|7 report provides no named population dataset or prevalence estimates for earlier chronic disease. It also supplies no sample size or measurement method behind the clinicians’ comparisons between younger patients and older adults. Those observations explain why the clinicians raised concerns, but they do not establish how widespread the pattern is. The appropriate reading is a report of clinical experience rather than a measured change across a population.
• There is no single agreed-upon biological-age measurement. Stanford Medicine explains that different clocks can assess different biological processes. Abi Al-Surur also identified epigenetic age and telomere length alongside inflammatory markers as research areas. These approaches should not be treated as interchangeable versions of one settled measurement. For context, AgeAmaze’s explanation of the different signals used by aging models provides a framework for comparing what a reported score represents before giving the number clinical significance.
• The sampled material limits the scope of the result. Stanford Medicine notes that a test may capture one biological compartment rather than whole-body aging. A result based on blood-cell DNA does not directly establish how other organs are aging. The interpretive boundary is therefore the biology actually sampled and measured. Describing such a result as the age of the entire person would extend its meaning beyond the evidence Stanford describes.
• A precise-looking number still contains uncertainty. Stanford Medicine attributes differences among tests partly to measurement error and biological noise. Its article quotes Anne Brunet cautioning against overinterpreting a single number. That concern is about how much weight the reported precision deserves, not simply whether a result appears reassuring or concerning. A useful interpretation keeps the measurement method and its uncertainty alongside the score instead of treating the number as self-explanatory.
• Clinical usefulness requires evidence about outcomes. David Rehkopf warned in Stanford Medicine’s account that consumer tests often lack strong outcome data. A test’s research value and its usefulness for an individual health decision are separate questions. For an intervention claim, a lower reported age would need to be connected to a meaningful health benefit rather than accepted as that benefit by itself. The practical question is what evidence supports the decision being proposed on the basis of the score.
• The report does not quantify lifestyle causes. Clinicians quoted by Emirates 24|7 pointed to inactivity and poor nutrition among possible contributors to earlier disease. They also discussed smoking and obesity alongside sleep disturbance, stress and social isolation. The article provides no analysis separating or quantifying those factors’ effects in the patients discussed. Their comments should therefore be read as clinical explanations, not as results from a study establishing why biological aging accelerated in a defined group.
• CRP is not a stand-alone aging assessment. Abi Al-Surur said C-reactive protein may be useful in certain medical conditions but is non-specific. She cautioned against using it alone as an aging test. The report supplies neither an aging threshold nor diagnostic-performance data for CRP. The relevant question is its purpose in a particular medical assessment, rather than whether an isolated result can serve as a general verdict on the pace of aging.

How to turn these limits into a useful clinical discussion

The practical alternative in the Emirates 24|7 report was not another method for calculating an age. It was an assessment organized around established disease-risk indicators. That changes the question from whether someone’s body is supposedly older than their birthday suggests to which health risks deserve attention in their circumstances.

Abi Al-Surur highlighted blood pressure and glycated haemoglobin, also called HbA1c. She also named blood lipids and cholesterol alongside waist circumference and body mass index. These were presented as practical indicators relevant to disease risk, not as ingredients in a calculation that diagnoses premature aging. A qualified clinician can discuss their relevance to an individual’s health assessment.

That distinction matters when deciding what information to seek. A discussion centered on disease risk asks what a measurement is intended to assess and how its result would inform care. AgeAmaze’s guide to matching a measurement to its intended clinical purpose offers related context for separating an aging estimate from a medical assessment.

Organ-function testing has its own place in that discussion. Abi Al-Surur said kidney and liver function should be assessed when medically necessary. The decision therefore depends on the clinical reason for testing rather than on a general ambition to obtain a biological-age profile. The report supports medically indicated assessment, not a routine organ-testing package for everyone interested in longevity.

The same individualized approach applies to additional screening and early cancer detection. The Emirates 24|7 report says these decisions should reflect age and sex alongside family history and individual risk factors. Reports of younger patients developing chronic conditions do not create a uniform screening schedule for all young adults. Personal screening decisions belong in a discussion with a qualified healthcare professional.

For someone considering a consumer age test, the first useful task is to clarify what question the result is supposed to answer. Research interest and personal curiosity are different purposes from investigating a medical concern. Keeping that purpose explicit helps prevent an informational product from quietly taking on a diagnostic role. Stanford Medicine’s account supports interpreting a score within its particular measurement context rather than assigning it authority over every aspect of health.

How research could establish clinical usefulness

The next step is research showing that a specified biological-age test reliably predicts meaningful health outcomes and improves clinical decisions beyond the information already available from established risk measures.

How AgeAmaze helps

Choosing the weight to give a biological-age result brings the reader to AgeAmaze’s focus on readable longevity research. The publication addresses exaggerated biomarker and emerging-therapy claims by placing scientific mechanisms beside the strength of their supporting evidence, giving skeptical adults context for judging a claim without mistaking an early result for a health promise.

Read the research

Sources

1. Biological age versus chronological age: What the science says
2. Doctors warn chronic diseases are appearing before 30 as biological ageing accelerates among young adults